Genetic Technologies to Launch Ground-breaking Comprehensive Risk Test for Breast & Ovarian Cancer
As discussed during the recent education session, the excess capacity for genetic testing post Covid is a resource that will be used.
This article refers to a proposed new saliva test for BRCA positive mutations. A commercial company; (Genetic Technologies) has developed it, the testing aimed at the US market, will be done in Fitzroy, Melbourne.
The expected positive rate is 0.5%, the company suggest a negative result will provide comfort. However, with the normal incidence of breast and ovarian cancer being much greater, this may be cold comfort. Apparently FDA approval is not required for Consumer Initiated Testing. Currently the legality in Australia is in doubt.
No comments:
Post a Comment